Earnings call: Mersana Therapeutics reports on ADC development progress

Published on 1 Mar 2024 on Investing.com

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ: MRSN ) has provided updates on its antibody-drug...

Read the rest of the article

Start tracking your investments with Statfolio

On January 15, Ashish Mandelia, Vice President and Chief Accounting Officer at Mersana Therapeuti...

Investing.com 18 Jan 2025

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN), a biotech company with a market...

Investing.com 18 Jan 2025

In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger...

Investing.com 18 Jan 2025

On January 15, Protopapas sold 6,191 shares of common stock at a price of $0.63 per share, amount...

Investing.com 17 Jan 2025

CAMBRIDGE, MA—Timothy B. Lowinger, the Senior Vice President and Chief Scientific and Technology...

Investing.com 17 Jan 2025

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, th...

Investing.com 17 Jan 2025

CAMBRIDGE, MA—Alejandra Carvajal, the Senior Vice President and Chief Legal Officer of Mersana...

Investing.com 17 Jan 2025

Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

On October 11, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) executed a significant...

GuruFocus.com · via Yahoo Finance 15 Oct 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) just released its quarterly report and things are lookin...

Simply Wall St. via Yahoo Finance 10 May 2024